Hyperion Therapeutics Receives Special Protocol Assessment Approval From FDA for Pivotal Phase III Trial in Urea Cycle Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the pivotal Phase III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea cycle disorders (UCD). The SPA is a written agreement between the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of the Phase III trial to be used in support of a New Drug Application (NDA).

MORE ON THIS TOPIC